Obeticholic Acid 10 MG

DRUG3 trials

Sponsors

Intercept Pharmaceuticals, King Edward Medical University

Conditions

Hepatic ImpairmentNon Alcoholic Fatty Liver DiseasePrimary Biliary Cholangitis

Phase 1

Hepatic Impairment Trial of Obeticholic Acid

CompletedNCT01904539

Intercept PharmaceuticalsHepatic Impairment

Start: 2013-06-30End: 2013-10-31Updated: 2013-10-24

Phase 2

Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease

CompletedNCT07104786

King Edward Medical UniversityNon Alcoholic Fatty Liver Disease

Start: 2023-08-24End: 2024-05-23Updated: 2025-08-05

Unknown Phase

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

WithdrawnNCT05293938

Intercept PharmaceuticalsPrimary Biliary Cholangitis

Start: 2022-03-28End: 2023-07-31Updated: 2023-10-10